ProCE Banner Activity

Rationale and Evidence for EZH1/2 Inhibitors in PTCL

Clinical Thought
Read this commentary for expert insights on the management of PTCL and emerging clinical trial evidence with EZH1/2 inhibitors in different PTCL subtypes.

Released: August 08, 2022

Expiration: August 07, 2023

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Pamela B. Allen

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Pierluigi Porcu

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Program Director Disclosure

Program Director

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD: consultant/advisor/speaker: Acrotech, Affimed, Cimeio Therapeutics, Daiichi Sankyo, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Secura Bio, Shoreline Biosciences, Takeda, Trillium, Tubulis, Vividion Therapeutics, Yingli Pharma; researcher: ADC Therapeutics, Affimed, C4 Therapeutics, Celgene, Crispr Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, Verastem/Secura Bio.

Faculty Disclosure

Primary Author

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Pamela B. Allen, MD: advisor: Daiichi Sankyo.

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Pierluigi Porcu, MD: consultant/advisor/speaker: Daiichi Sankyo, Dren Bio, Innate Pharma, Loxo Oncology, MorphoSys, Viracta.